World Health Organization (WHO) Collaborating Centre for Gonorrhoea and other STIs, Örebro University Hospital and Örebro University, Örebro, Sweden
Gonorrhoea is a major public health concern internationally, with increasing incidence and sporadic ceftriaxone-resistant cases, including treatment failures. This talk will present and discuss the recently published ‘2020 European guideline for the diagnosis and treatment of gonorrhoea in adults’ (Unemo M, Ross JDC, Serwin AB, Gomberg M, Cusini M, Jensen JS. Int J STD AIDS. 2020). The updates and recommendations of the 2020 European Gonorrhoea guideline emphasize the increasing gonorrhoea incidence; broad indications for enhanced testing with validated and quality-assured NAATs and culture; dual antimicrobial therapy including high dose of ceftriaxone and azithromycin (ceftriaxone 1 g plus azithromycin 2 g) OR ceftriaxone 1 g monotherapy (ONLY where i) comprehensive, recent and quality-assured local in vitro ceftriaxone susceptibility testing has shown lack of ceftriaxone resistance; ii) test of cure (TOC) is mandatory and the patient is very likely to return for TOC; and iii) recommended doxycycline regimen is given to cover any concomitant C. trachomatis infection, i.e. if C. trachomatis infection has not been excluded by NAAT) for uncomplicated gonorrhoea when the antimicrobial susceptibility is unknown; recommendation of TOC in all gonorrhoea cases to ensure eradication of infection and identify resistance; and enhanced surveillance of treatment failures with recommended treatment regimens. Significant improvements are imperative to manage and control gonorrhoea and to mitigate the emergence and/or spread of ceftriaxone-, multidrug- and extensively drug-resistant gonorrhoea.
34 IUSTI Congress - European Congres on Sexually transmitted Infections and HIV/AIDS
TAMING THE TIDE of STIs & HIV
Bucharest, September 3-5,